A new global coalition announced a new campaign on Tuesday to get psilocybin mushrooms internationally rescheduled.
As the psychedelics reform movement continues to expand domestically in the U.S., the International Therapeutic Psilocybin Rescheduling Initiative (ITPRI) is seeking a worldwide policy change in order to facilitate research into the therapeutic potential of the substance.
Partners of the coalition include the Multidisciplinary Association for Psychedelic Studies (MAPS), Beckley Foundation, Mind Medicine Australia, Drug Science and Open Foundation.
The initiative focuses on international drug scheduling under the United Nations’s 1971 Convention on Psychotropic Substances, which currently places psilocybin in the most tightly restricted, Schedule I category, which is supposed to be reserved for drugs that constitute “an especially serious risk” and have “limited” therapeutic uses.
Advocates say that psilocybin fits neither of those criteria.